Long-term ocular outcome in congenital toxoplasmosis: A prospective cohort of treated children

Journal of Infection

Volumn 64, Issue 1, 2012, Pages 104-109

  Faucher, B ^a   Garcia Meric, P ^b   Franck, J ^a   Minodier, P ^c   Francois, P ^d   Gonnet, S ^a   L'ollivier, C ^a   Piarroux, R ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c HÔPITAL NORD   (France)

^d HÔPITAL SAINT JOSEPH   (France)

Author keywords

Chorioretinitis; Congenital toxoplasmosis; Long term care; Prenatal diagnosis; Pyrimethamine; Spiramycin; Sulfadiazine; Toxoplasma gondii; Visual impairment

Indexed keywords

FOLINIC ACID; PYRIMETHAMINE PLUS SULFADOXINE; SPIRAMYCIN;

ADOLESCENT; ADULT; AMNION FLUID; ANEMIA; ARTICLE; CHILD; CHORIORETINITIS; COHORT ANALYSIS; CONGENITAL TOXOPLASMOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ERUPTION; EYE INJURY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MATERNAL DISEASE; NEUTROPENIA; ONSET AGE; OUTCOME ASSESSMENT; POSTNATAL CARE; PRENATAL CARE; PROSPECTIVE STUDY; RETINA MACULOPATHY; RISK FACTOR; SEROLOGY; TREATMENT DURATION; VISUAL IMPAIRMENT; VOMITING;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FRANCE; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; PREGNANCY; PROSPECTIVE STUDIES; TOXOPLASMOSIS, CONGENITAL; TOXOPLASMOSIS, OCULAR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84455169537     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.10.008     Document Type: Article

References (31)

1. Montoya J.G., Remington J.S. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2008, 47(4):554-566.
2. Freeman K., Tan H.K., Prusa A., Petersen E., Buffolano W., Malm G., et al. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics 2008, 121(5):1215-1222.
3. Cortina-Borja M., Tan H.K., Wallon M., Paul M., Prusa A., Buffolano W., et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 2010, 7(10). pii: e1000351.
4. Thiébaut R., Leproust S., Chêne G., Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007, 369(9556):115-122. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group.
5. Phan L., Kasza K., Jalbrzikowski J., Noble A.G., Latkany P., Kuo A., et al. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol 2008, 146(3):375-384.
6. Phan L., Kasza K., Jalbrzikowski J., Noble A.G., Latkany P., Kuo A., et al. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophtalmology 2008, 115:553-559.
7. Berrebi A., Assouline C., Bessières M.H., Lathière M., Cassaing S., Minville V., et al. Long-term outcome of children with congenital toxoplasmosis. Am J Obstet Gynecol 2010, 203(6):552.e1-552.e6.
8. Koppe J.G., Loewer-Sieger D.H., de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986, 1(8475):254-256.
9. Wallon M., Kodjikian L., Binquet C., Garweg J., Fleury J., Quantin C., et al. Long term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004, 113:1567-1572.
10. Meenken C., Assies J., Van Nieuwenhvisen O., Holwerda-Van Der Maat W.G., Van Schooneweld M.J., Delleman W.J., et al. Long term ocular and neurological involvement in severe ocular toxoplasmosis. Brit Journ Ophtalmol 1995, 79:581-584.
11. Gilbert R.E., Freeman K., Lago E.G., Bahia-Oliveira L.M., Tan H.K., Wallon M., et al. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis 2008, 2(8):e277.
12. Wilson C.B., Remington J.S., Stagno S., Reynolds D.W. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980, 66(5):767-774.
13. Binquet C., Wallon M., Quantin C., Kodjikian L., Garweg J., Fleury J., et al. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect 2003, 131(3):1157-1168.
14. Gras L., Wallon M., Pollak A., Cortina-Borja M., Evengard B., Hayde M., et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr 2005, 94(12):1721-1731.
15. Hohlfeld P., Daffos F., Thulliez P., Aufrant C., Couvreur J., MacAleese J., et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989, 115:765-769.
16. Kieffer F., Wallon M., Garcia P., Thulliez P., Peyron F., Franck J. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J 2008, 27(1):27-32.
17. McLeod R., Kieffer F., Sautter M., Hosten T., Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis?. Mem Inst Oswaldo Cruz 2009, 104(2):320-344.
18. Peyron F., Garweg J.G., Wallon M., Descloux E., Rolland M., Barth J. Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance. Pediatr Infect Dis J 2011, 30(7):597-600.
19. Sauer A., de la Torre A., Gomez-Marin J., Bourcier T., Garweg J., Speeg-Schatz C., et al. Prevention of retinochoroiditis in congenital toxoplasmosis: europe versus South America. Pediatr Infect Dis J 2011, 30(7):601-603.
20. McLeod R., Boyer K., Karrison T., Kasza K., Swisher C., Roizen N., et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Clin Infect Dis 2006, 42(10):1383-1394.
21. Thulliez P. Commentary: efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. Int J Epidemiol 2001, 30(6):1315-1316.
22. Macones G.A., McNamara J., Wallenstein M., Squires K. Discussion: 'Congenital toxoplasmosis' by Berrébi et al. Am J Obstet Gynecol 2010, 203(6):e1-3.
23. Gilbert R.E., Stanford M.R. Is ocular toxoplasmosis caused by prenatal or postnatal infection?. Br J Ophthalmol 2000, 84(2):224-226.
24. Delair E., Monnet D., Grabar S., Dupouy-Camet J., Yera H., Brézin A.P. Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J Ophthalmol 2008, 146(6):851-855.
25. Tan H.K., Schmidt D., Stanford M., Teär-Fahnehjelm K., Ferret N., Salt A., et al. Risk of visual impairment in children with congenital toxoplasmic retinochoroiditis. Am J Ophthalmol 2007, 144(5):648-653.
26. Kodjikian L., Wallon M., Fleury J., Denis P., Binquet C., Peyron F., et al. Ocular manifestations in congenital toxoplasmosis. Graefe's Arch Clin Exp Ophtal 2006, 244:14-21.
27. Gilbert R., Gras L. European multicentre study on congenital toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 2003, 110(2):112-120.
28. Foulon W., Villena I., Stray-Pedersen B., Decoster A., Lappalainen M., Pinon J.M., et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999, 180:410-415.
29. Daveluy A., Haramburu F., Bricout H., Di Costanzo S., Fourrier A., Tan H.K., et al. Review of data related to side effects of drugs used in congenital toxoplasmosis 2005, EUROTOXO, A European Consensus on the State of the Science, Bordeaux, France.
30. Maubon D., Ajzenberg D., Brenier-Pinchart M.P., Dardé M.L., Pelloux H. What are the respective host and parasite contributions to toxoplasmosis?. Trends Parasitol 2008, 24(7):299-303.
31. Dubey J.P., Sundar N., Hill D., Velmurugan G.V., Bandini L.A., Kwok O.C., et al. High prevalence and abundant atypical genotypes of Toxoplasma gondii isolated from lambs destined for human consumption in the USA. Int J Parasitol 2008, 38(8-9):999-1006.